Company intelligence / Profile preview

SlimBiotics GmbH

Ownership: Private
Development stage: Commercial

Overview

SlimBiotics has demonstrated in a double-blind randomized controlled clinical study that its proprietary probiotic formulation significantly improves weight management metrics—including body weight, BMI, body fat mass—and markers of metabolic health compared to placebo. Additional studies are underway globally to further validate these findings[2][6].

Therapeutic areas: Metabolic DisordersEndocrinology
Modalities: Probiotic strains (primarily plant-derived probiotics from fermented foods such as Kimere)[5][6]
Industry: Non-Drug Biotech

Drug pipeline

1 asset

slimbiotics

Commercial

Indications: Obesity, Metabolic disorders

Partnerships

DSM i-Health for North America and China—commercialization under Culturelle and Estroven brandsSUPCS collaboration for Israel market entry[5].

Beyond the preview

Go deeper on SlimBiotics GmbH.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SlimBiotics GmbH.

Explore the full profile